87 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author신수진-
dc.date.accessioned2019-11-27T20:45:46Z-
dc.date.available2019-11-27T20:45:46Z-
dc.date.issued2017-07-
dc.identifier.citationAMERICAN JOURNAL OF ROENTGENOLOGY, v. 209, no. 1, page. 1-9en_US
dc.identifier.issn0361-803X-
dc.identifier.issn1546-3141-
dc.identifier.urihttps://www.ajronline.org/doi/10.2214/AJR.16.16981-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/115007-
dc.description.abstractOBJECTIVE. The purpose of this study was to analyze the utility of the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) in the detection of a clinically significant cancers in patients with prostate cancers with a biopsy Gleason score of 6. MATERIALS AND METHODS. A group of 182 consecutively registered patients with biopsy-proven prostate cancer with a Gleason score of 6 underwent MRI and radical prostatectomy. Clinically significant cancer was surgically defined as Gleason score of 7 or greater, tumor volume of 0.5 cm(3) or greater, or tumor category T3 or greater. Clinical parameters (prostate-specific antigen level, greatest percentage of biopsy core, and percentage of positive cores) and the PI-RADSv2 ratings by three independent readers (experienced readers 1 and 2, inexperienced reader 3) were investigated. Cutoffs and the diagnostic performance of PI-RADSv2 for clinically significant cancer were analyzed. RESULTS. Clinically significant cancer was found in 87.4% (159/182) of patients. The cutoff PI-RADSv2 score for clinically significant cancer was 4 for readers 1 and 2 and 5 for reader 3. The AUCs were 0.829 and 0.853 for readers 1 and 2 (p < 0.001) and 0.602 for reader 3 (p = 0.067). For reader 1, sensitivity was 89.9% (143/159); specificity, 69.6% (16/23); positive predictive value, 95.3% (143/150); negative predictive value, 50.0% (16/32); and accuracy, 87.4% (159/182). The corresponding values for reader 2 were 81.1% (129/159), 82.6% (19/23), 97.0% (129/133), 38.8% (19/49), and 81.3% (148/182). For the experienced readers, 66.7-81.3% of patients with false-negative results had clinically significant cancers with tumor volume less than 1 c(m)3. CONCLUSION. PI-RADSv2 may help experienced readers identify clinically significant prostate cancers in patients with a biopsy Gleason score of 6. However, some small (< 1 cm3) clinically significant cancers can be missed when PI-RADSv2 is used.en_US
dc.language.isoen_USen_US
dc.publisherAMER ROENTGEN RAY SOCen_US
dc.subjectclinically significant canceren_US
dc.subjectGleason scoreen_US
dc.subjectMRIen_US
dc.subjectPI-RADSen_US
dc.subjectprostate canceren_US
dc.titlePI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Canceren_US
dc.typeArticleen_US
dc.relation.no1-
dc.relation.volume209-
dc.identifier.doi10.2214/AJR.16.16981-
dc.relation.page1-9-
dc.relation.journalAMERICAN JOURNAL OF ROENTGENOLOGY-
dc.contributor.googleauthorSeo, Ji Won-
dc.contributor.googleauthorShin, Su-Jin-
dc.contributor.googleauthorOh, Young Taik-
dc.contributor.googleauthorJung, Dae Chul-
dc.contributor.googleauthorCho, Nam Hoon-
dc.contributor.googleauthorChoi, Young Deuk-
dc.contributor.googleauthorPark, Sung Yoon-
dc.relation.code2017002345-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidcharm-
dc.identifier.researcherIDK-3248-2017-
dc.identifier.orcidhttp://orcid.org/0000-0001-9114-8438-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE